Evid Invest
Holders — by stockHoldings — by fund

KVP Capital Advisors, LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001858198

$136.2M

disclosed book value

35

positions

10.5%

largest position share

Positions, as of 2026-06-30

top 35 of 35 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1PRAXPRAXIS PRECISION MEDICINES I42,900$14.4M10.5%
2WHWKWHITEHAWK THERAPEUTICS INC2.2M$9.9M7.3%
3ERASERASCA INC455,000$8.3M6.1%
4TRVITREVI THERAPEUTICS INC414,000$7.7M5.7%
5STROSUTRO BIOPHARMA INC226,575$7.5M5.5%
6TNGXTANGO THERAPEUTICS INC230,264$7.2M5.3%
7MBXMBX BIOSCIENCES INC121,524$6.7M4.9%
8PTGXPROTAGONIST THERAPEUTICS INC53,000$6.5M4.8%
9EWTXEDGEWISE THERAPEUTICS INC133,000$5.4M4%
10TNDMTANDEM DIABETES CARE INC301,000$4.5M3.3%
11IRONDISC MEDICINE INC58,250$4.3M3.1%
12SVRASAVARA INC605,280$3.7M2.7%
13AVBPARRIVENT BIOPHARMA INC102,000$3.5M2.6%
14INSMINSMED INC28,497$3.0M2.2%
15ACHVACHIEVE LIFE SCIENCES INC462,355$3.0M2.2%
16IDYAIDEAYA BIOSCIENCES INC79,700$3.0M2.2%
17OCULOCULAR THERAPEUTIX INC300,000$2.9M2.2%
18AXSMAXSOME THERAPEUTICS INC.12,000$2.9M2.2%
19DSGNDESIGN THERAPEUTICS INC185,000$2.7M2%
20UTHRUNITED THERAPEUTICS CORP DEL4,750$2.6M1.9%
21SRRKSCHOLAR ROCK HLDG CORP45,000$2.5M1.8%
22IMMXIMMIX BIOPHARMA INC230,423$2.4M1.7%
23VRDNVIRIDIAN THERAPEUTICS INC125,000$2.3M1.7%
24MLYSMINERALYS THERAPEUTICS INC84,168$2.3M1.7%
25DRUGBRIGHT MINDS BIOSCIENCES INC31,813$2.2M1.6%
26TVTXTRAVERE THERAPEUTICS INC39,000$2.2M1.6%
27ZURA BIO LTD373,128$2.2M1.6%
28ARTVARTIVA BIOTHERAPEUTICS INC200,000$1.9M1.4%
29NKTRNEKTAR THERAPEUTICS26,900$1.9M1.4%
30CMPXCOMPASS THERAPEUTICS INC771,000$1.7M1.2%
31CABACABALETTA BIO INC505,431$1.6M1.2%
32VERAVERA THERAPEUTICS INC32,700$1.4M1%
33EOLSEVOLUS INC150,000$1.0M0.8%
34CELCCELCUITY INC4,000$418,4800.3%
35MNLOUSDVYNE THERAPEUTICS INC500,551$325,7090.2%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.